Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

The Centers for Disease Control and Prevention is urging some people to get additional doses of the COVID-19 vaccine for ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...

Shawn Johnson East is an Olympic and Dancing with the Stars champion who earned serious “cool mom” street cred in 2023 when ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

But there’s another virus out there that can also cause these symptoms: It’s called respiratory syncytial virus (RSV), and ...